MADRIGAL PHARMACEUTICALS INC
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
MDGL$432.60-0.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Cash flows from operating activities: | |||
| Net loss | $(373,630) | $(295,350) | $(241,846) |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Stock-based compensation expense | 49,735 | 31,625 | 26,873 |
| Depreciation and amortization expense | 527 | 467 | 405 |
| Amortization of debt issuance costs and discount | 2,414 | 797 | — |
| Changes in operating assets and liabilities: | |||
| Prepaid expenses and other current assets | (555) | (1,257) | (325) |
| Accounts payable | 4,210 | 2,451 | 20,363 |
| Accrued expense | (1,481) | 36,413 | 9,826 |
| Accrued interest, net of interest received on maturity of investments | (5,450) | (3) | 787 |
| Net cash used in operating activities | (324,230) | (224,857) | (183,917) |
| Cash flows from investing activities: | |||
| Purchases of marketable securities | (834,439) | (143,478) | (394,120) |
| Sales and maturities of marketable securities | 333,398 | 350,381 | 389,274 |
| Purchases of property and equipment, net of disposals | (1,479) | (217) | (209) |
| Net cash provided by (used in) investing activities | (502,520) | 206,686 | (5,055) |
| Cash flows from financing activities: | |||
| Proceeds from issuances of stock, excluding related parties, net of transaction costs | 260,187 | 255,382 | 170,207 |
| Proceeds from the sale of related party warrants and stock and exercise of common stock options, net of transaction costs | 270,292 | 8,955 | 1,030 |
| Proceeds from issuance of loan payable | 65,000 | 50,000 | — |
| Payment of debt issuance costs | (363) | (886) | — |
| Net cash provided by financing activities | 595,116 | 313,451 | 171,237 |
| Net increase (decrease) in cash and cash equivalents | (231,634) | 295,280 | (17,735) |
| Cash and cash equivalents at beginning of period | 331,549 | 36,269 | 54,004 |
| Cash and cash equivalents at end of period | $99,915 | $331,549 | $36,269 |
| Supplemental disclosure of cash flow information: | |||
| Obtaining a right-of-use asset in exchange for a lease liability | $1,628 | $583 | $376 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.